Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
scFvαIIbβ3 mRNA
- Development stage
- Preclinical
- Lead developer
- Baker Heart and Diabetes Institute
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
scFvαIIbβ3 mRNA is an investigational mRNA-based therapeutic encoding a conformation-specific single-chain variable fragment (scFvαIIbβ3) that selectively targets the activated platelet integrin GPIIb/IIIa (integrin αIIbβ3). Developed by the Baker Heart and Diabetes Institute, this therapeutic is designed for safer thromboprophylaxis. By selectively binding to the activated conformation of GPIIb/IIIa, the expressed scFv inhibits pathological thrombosis while preserving physiological hemostasis, thereby mitigating the bleeding risks associated with conventional antiplatelet therapies. The mRNA is formulated in a novel lipid nanoparticle system (OryKL) composed of γ-oryzanol and DLin-KC2-DMA for systemic delivery. Preclinical studies have demonstrated that both conventional mRNA and self-amplifying mRNA (samRNA) constructs provide durable antithrombotic protection in vivo without prolonging bleeding times or causing systemic toxicity.
- Other names
- platelet-targeted self-amplifying mRNAscFvαIIbβ3 samRNAscFvαIIbβ3 self-amplifying mRNAscFvαIIbβ3-encoding mRNA
02
Targets
GPIIb/IIIa (Integrin alpha-IIb/beta-3)
Beyond the preview
Go deeper on scFvαIIbβ3 mRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on scFvαIIbβ3 mRNA.